Lilly chooses another Corcept compound to combat Zyprexa weight gain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor
You may also be interested in...
Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
Corcept will begin the first of two pivotal Phase III trials for Corlux (mifepristone) for treatment of psychotic features of psychotic major depression "immediately," the firm said.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.